Insulet Corporation (PODD) - What Are Researchers Saying About This Stock?

Key Points

• Analyst consensus is “Hold” among 26 brokerages, with 13 buy, 12 hold and one sell rating. The average 12-month price target is $186.68, though several firms recently lowered their targets.
• Insulet reported quarterly EPS of $1.66, beating estimates of $1.47, while revenue rose 23.5% year over year to $801.7 million. Analysts expect approximately $6.51 in EPS for the current year.
• Institutional interest has increased, including major new positions from BlackRock, Man Group, Bank of America and Bank of New York Mellon, while Arrowstreet Capital expanded its stake by 462.7%.

Insulet Corporation (NASDAQ:PODD - Get Free Report) has been assigned an average rating of "Hold" from the twenty-six brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and thirteen have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $186.68.

PODD has been the topic of a number of recent analyst reports. Wall Street Zen lowered Insulet from a "buy" rating to a "hold" rating in a report on Saturday. Sanford C. Bernstein decreased their price target on Insulet from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. TD Cowen reduced their price objective on shares of Insulet from $294.00 to $144.00 and set a "hold" rating on the stock in a research note on Thursday, August 6th. Evercore set a $180.00 target price on shares of Insulet in a report on Monday, July 6th. Finally, Jefferies Financial Group cut their price target on shares of Insulet from $275.00 to $190.00 and set a "buy" rating for the company in a report on Monday, October 12th.

Insulet Stock Up 0.6%

Shares of Insulet stock opened at $149.01 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company has a market capitalization of $10.33 billion, a P/E ratio of 27.85, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. The business has a 50-day moving average of $140.58 and a two-hundred day moving average of $154.66. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business's quarterly revenue was up 23.5% on a year-over-year basis. During the same period last year, the business earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities analysts predict that Insulet will post 6.51 EPS for the current year.

Institutional Investors Weigh In On Insulet

Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Insulet during the second quarter valued at $1,018,582,000. Arrowstreet Capital Limited Partnership increased its position in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Man Group plc acquired a new stake in Insulet during the 2nd quarter valued at approximately $78,746,000. Bank of America Corp DE bought a new position in Insulet during the 2nd quarter worth approximately $64,921,000. Finally, Bank of New York Mellon Corp bought a new position in Insulet during the 2nd quarter worth approximately $60,615,000.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.